{"ATC Code":"N04BX02","Abbreviation":"","Aliases":["Comtan","Comtess","Entacapona","Entacaponum","OR-611","Entacom","Entacapone teva","Entacapone orion","OR 611","(E)-Entacapone"],"Biological Half-Life":"0.4-0.7 hour","CAS":"130929-57-6","ChEBI":"CHEBI:4798","ChEMBL":"CHEMBL953","ChemicalClasses":[],"Chirality":"achiral","Color/Form":"Crystals from acetic acid + hydrochloric acid","Dosing Info":[],"Drug Classes":"Breastfeeding; Lactation; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors;","Drug Indication":"Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose \"wearing-off\".","Drug Warnings":"Diarrhea was reported in 10% of patients receiving entacapone in clinical studies, and about 2% of patients required discontinuance of the drug because of diarrhea. Diarrhea generally was of mild to moderate intensity, but severe diarrhea, which required hospitalization, may occur rarely.  Diarrhea generally occurs during the first 4-12 weeks of entacapone therapy, but may occur as early as the first week or as late as several months following initiation of entacapone therapy. Diarrhea generally resolved following discontinuance of the drug.","DrugClasses":[],"European Community (EC) Number":"603-449-6","FDA Pharmacological Classification":"4975G9NM6T","HMDB ID":"HMDB0012226","HeavyAtomCount":22,"Human Drugs":"Breastfeeding; Lactation; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors;","IUPACName":"(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide","Impurities":["entacapone 3-methyl ether","desethyl-entacapone","entacapone, (z)-","denitroentacapone"],"InChI":"InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+","InChIKey":"JRURYQJSLYLRLN-BJMVGYQFSA-N","MeSH Pharmacological Classification":"Compounds and drugs that inhibit or block the activity of CATECHOL O-METHYLTRANSFERASE enzymes. Drugs in this class are used in management of central nervous system disorders such as PARKINSON DISEASE. (See all compounds classified as Catechol O-Methyltransferase Inhibitors.)","Melting Point":"162-163 °C","MolecularFormula":"C\u003csub\u003e14\u003c/sub\u003eH\u003csub\u003e15\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO\u003csub\u003e5\u003c/sub\u003e","MolecularWeight":"305.29 g/mol","PD":"PD9","Pharmacodynamics":"Entacapone is structurally and pharmacologically related to tolcapone, but unlike tolcapone, is not associated with hepatotoxicity. Entacapone is used in the treatment of Parkinson\u0026rsquo;s disease as an adjunct to levodopa/carbidopa therapy. Entacapone selectively and reversiblly inhibits catechol-O-methyltransferase (COMT). In mammals, COMT is distributed throughout various organs with the highest activities in the liver and kidney. COMT also occurs in the heart, lung, smooth and skeletal muscles, intestinal tract, reproductive organs, various glands, adipose tissue, skin, blood cells and neuronal tissues, especially in glial cells. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa, catalyzing the it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery.","Physical Description":"Solid","PrevSalts":[],"PubChemId":5281081,"Record Description":["Entacapone is a monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group. It has a role as an EC 2.1.1.6 (catechol O-methyltransferase) inhibitor, an antiparkinson drug, a central nervous system drug and an antidyskinesia agent. It is a monocarboxylic acid amide, a nitrile, a member of catechols and a member of 2-nitrophenols.","Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor.","Entacapone is a Catechol-O-Methyltransferase Inhibitor. The mechanism of action of entacapone is as a Catechol O-Methyltransferase Inhibitor.","Entacapone is a catechol-O-methyltransferase inhibitor used in the therapy of Parkinson disease as adjunctive therapy in combination with levodopa and carbidopa. Entacapone has been associated with a low rate of serum enzyme elevations during treatment, but has yet to be implicated in cases of clinically apparent acute liver injury with jaundice.","Entacapone is a nitrocatechol compound with anti-parkinsonian property. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure including dihydroxyphenylalanine (DOPA), catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. When administered in conjunction with dopaminergic agents such as L-DOPA, entacapone prevents the metabolism and inactivation of adjunct drugs, thereby increasing the bioavailability of these compounds by facilitating their passage across the blood-brain barrier.","ENTACAPONE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for parkinson disease and has 5 investigational indications.","Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor.","See also: Carbidopa; entacapone; levodopa (component of).","Entacapone is a monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group. It has a role as an EC 2.1.1.6 (catechol O-methyltransferase) inhibitor, an antiparkinson drug, a central nervous system drug and an antidyskinesia agent. It is a monocarboxylic acid amide, a nitrile, a member of catechols and a member of 2-nitrophenols.","LiverTox|CNS|Parkinsons agent|COMT inhibitor"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Entacapone","Name":"Entacapone","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q416444","Name":"Entacapone","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00494","Name":"Entacapone","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5281081","Name":"Entacapone","Sub":false}]},{"Name":"ChemSpider","Urls":[{"Link":"https://www.chemspider.com/Chemical-Structure.4444537.html","Name":"Entacapone","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL953","Name":"Entacapone","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4798","Name":"Entacapone","Sub":false}]},{"Name":"Probes \u0026 Drugs","Urls":[{"Link":"https://www.probes-drugs.org/compound/PD9","Name":"Entacapone","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=130929-57-6","Name":"Entacapone","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0012226","Name":"Entacapone","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07943","Name":"Entacapone","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/4975G9NM6T","Name":"Entacapone","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID5046439","Name":"Entacapone","Sub":false}]}],"SMILES":"CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N","Stability/Shelf Life":"Stable under recommended storage conditions.","StoreUNII":["4975G9NM6T"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="67.271mm" version="1.2" viewBox="0 0 135.859 67.271" width="135.859mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="68.0" stroke="none" width="136.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="134.821" x2="121.622" y1="26.077" y2="18.459"/>
                  
            <line class="bond" id="mol1bnd2" x1="121.622" x2="111.578" y1="18.459" y2="24.26"/>
                  
            <line class="bond" id="mol1bnd3" x1="108.425" x2="108.427" y1="29.931" y2="41.321"/>
                  
            <line class="bond" id="mol1bnd4" x1="108.427" x2="121.626" y1="41.321" y2="48.939"/>
                  
            <line class="bond" id="mol1bnd5" x1="105.271" x2="95.225" y1="24.261" y2="18.463"/>
                  
            <g class="bond" id="mol1bnd6">
                        
                <line x1="94.006" x2="94.004" y1="19.167" y2="7.145"/>
                        
                <line x1="96.444" x2="96.443" y1="19.167" y2="7.144"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="94.004" x2="94.005" y1="7.145" y2="13.156"/>
                <line class="hi" stroke="#FF0D0D" x1="96.443" x2="96.4435" y1="7.144" y2="13.1555"/>
            </g>
                  
            <line class="bond" id="mol1bnd7" x1="95.225" x2="82.028" y1="18.463" y2="26.085"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="68.829" x2="82.028" y1="18.468" y2="26.085"/>
                        
                <line x1="68.829" x2="79.59" y1="21.283" y2="27.494"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="68.829" x2="55.632" y1="18.468" y2="26.09"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="55.632" x2="42.424" y1="26.09" y2="18.47"/>
                        
                <line x1="53.193" x2="42.424" y1="27.498" y2="21.285"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="42.424" x2="29.216" y1="18.47" y2="26.09"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="29.216" x2="29.216" y1="26.09" y2="41.33"/>
                        
                <line x1="31.654" x2="31.654" y1="27.498" y2="39.921"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="29.216" x2="42.424" y1="41.33" y2="48.95"/>
                  
            <g class="bond" id="mol1bnd14">
                        
                <line x1="42.424" x2="55.632" y1="48.95" y2="41.33"/>
                        
                <line x1="42.424" x2="53.193" y1="46.135" y2="39.921"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd15" x1="55.632" x2="55.632" y1="26.09" y2="41.33"/>
                  
            <line class="bond" id="mol1bnd16" x1="42.424" x2="42.424" y1="48.95" y2="60.268"/>
                  
            <line class="bond" id="mol1bnd17" x1="29.216" x2="19.297" y1="41.33" y2="47.059"/>
                  
            <line class="bond" id="mol1bnd18" x1="29.216" x2="19.707" y1="26.09" y2="20.598"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="13.475" x2="6.707" y1="21.344" y2="25.249"/>
                        
                <line x1="12.256" x2="5.488" y1="19.232" y2="23.137"/>
                      
                <line class="hi" stroke="#3050F8" x1="13.475" x2="10.091" y1="21.344" y2="23.2965"/>
                <line class="hi" stroke="#FF0D0D" x1="6.707" x2="10.091" y1="25.249" y2="23.2965"/>
                <line class="hi" stroke="#3050F8" x1="12.256" x2="8.872" y1="19.232" y2="21.1845"/>
                <line class="hi" stroke="#FF0D0D" x1="5.488" x2="8.872" y1="23.137" y2="21.1845"/>
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="16.019" x2="16.02" y1="14.251" y2="7.149"/>
                  
            <line class="bond" id="mol1bnd21" x1="82.028" x2="82.031" y1="26.085" y2="41.325"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="82.031" x2="82.032" y1="41.325" y2="52.716"/>
                        
                <line x1="84.469" x2="84.471" y1="41.325" y2="52.715"/>
                        
                <line x1="79.592" x2="79.594" y1="41.326" y2="52.716"/>
                      
                <line class="hi" stroke="#3050F8" x1="82.032" x2="82.0315" y1="52.716" y2="47.0205"/>
                <line class="hi" stroke="#3050F8" x1="84.471" x2="84.47" y1="52.715" y2="47.02"/>
                <line class="hi" stroke="#3050F8" x1="79.594" x2="79.59299999999999" y1="52.716" y2="47.021"/>
            </g>
                  
            <path class="atom" d="M110.365 28.531h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .733v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.005 -.108 -.017 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M97.482 3.22q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.316 -.756 -.887q-.245 -.572 -.245 -1.334q.0 -.75 .245 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM93.618 3.22q.0 .923 .387 1.459q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.928 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.227 .524q-.393 .524 -.393 1.452z" id="mol1atm7" stroke="none"/>
                  
            <g class="atom" id="mol1atm16">
                        
                <path d="M44.683 64.187q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.245 -.571 -.245 -1.333q.0 -.75 .245 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM40.819 64.187q.0 .922 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M48.989 66.639h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.619v4.899z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm17">
                        
                <path d="M18.278 48.949q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.245 -.571 -.245 -1.333q.0 -.75 .245 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM14.414 48.949q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M13.198 51.402h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm18">
                        
                <path d="M17.959 20.917h-.72l-2.619 -4.066h-.03q.012 .238 .03 .596q.023 .357 .023 .732v2.738h-.565v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M19.635 15.873h.818v.293h-.818v.847h-.296v-.847h-.818v-.293h.818v-.85h.296v.85z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M5.078 26.083q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .566 .256 1.328zM1.215 26.083q-.0 .922 .387 1.458q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm19" stroke="none"/>
                  
            <g class="atom" id="mol1atm20">
                        
                <path d="M18.28 3.225q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .31 .756 .875q.256 .566 .256 1.328zM14.417 3.225q-.0 .922 .387 1.458q.393 .53 1.22 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M20.774 .56v.293h-1.932v-.293h1.932z" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M83.974 59.015h-.721l-2.619 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" id="mol1atm22" stroke="none"/>
                
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="111.578" x2="116.6" y1="24.26" y2="21.3595"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="108.425" x2="108.426" y1="29.931" y2="35.626"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="105.271" x2="100.24799999999999" y1="24.261" y2="21.362000000000002"/>
            <line class="hi" id="mol1bnd16" stroke="#FF0D0D" x1="42.424" x2="42.424" y1="60.268" y2="54.609"/>
            <line class="hi" id="mol1bnd17" stroke="#FF0D0D" x1="19.297" x2="24.256500000000003" y1="47.059" y2="44.1945"/>
            <line class="hi" id="mol1bnd17" stroke="#FF0D0D" x1="19.297" x2="24.256500000000003" y1="47.059" y2="44.1945"/>
            <line class="hi" id="mol1bnd18" stroke="#3050F8" x1="19.707" x2="24.4615" y1="20.598" y2="23.344"/>
            <line class="hi" id="mol1bnd18" stroke="#3050F8" x1="19.707" x2="24.4615" y1="20.598" y2="23.344"/>
            <line class="hi" id="mol1bnd20" stroke="#3050F8" x1="16.019" x2="16.0195" y1="14.251" y2="10.7"/>
            <line class="hi" id="mol1bnd20" stroke="#3050F8" x1="16.019" x2="16.0195" y1="14.251" y2="10.7"/>
            <line class="hi" id="mol1bnd20" stroke="#FF0D0D" x1="16.02" x2="16.0195" y1="7.149" y2="10.7"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Antiparkinson Agents; Enzyme Inhibitors","Title":"Entacapone","UNII":"4975G9NM6T","Wikidata":"Q416444","XLogP":2.1}